期刊文献+

真核细胞始动因子4E结合蛋白1在乳腺癌信号传导通路中的作用及其与预后的关系 被引量:1

The effect of initiation factor 4E-binding protein 1 in the cell signaling pathways of breast cancer
原文传递
导出
摘要 对本院48例乳腺癌患者术后肿瘤组织的细胞信号传导通路的人类表皮生长因子受体2(HEPO)、丝氨酸与苏氨酸激酶(Akt)、真核细胞始动因子4E结合蛋白1(4EBP1)、核糖体蛋白S6激酶1(p70S6K1)和核糖体S6行免疫组化染色检测。HER2阳性与阴性表达的肿瘤比较,Akt表达率更高(P〈0.01)。Akt表达的水平与其下游因子4EBP1、p70S6K1的表达呈正相关(P〈0.01,P〈0.05)。4EBP1主要表达在低分化的肿瘤中(P〈0.01),并与肿瘤大小(P〈0.05)、淋巴结的转移(P〈0.01)及局部复发相关(P〈0.01)。提示4EBP1与乳腺癌的肿瘤分级和预后密切相关。 The expression of human epidermal growth factor receptor 2 (HER2), serine-threonine kinase (Akt), 4E-binding protein (4EBP1), phophorylated ribosomal protein S6 kinasel (pTOS6KI) and ribosomal protein S6 (S6) were detected with immunohistoehemistry in 48 cases of human breast cancer. Tumors high-expressing HER2 showed higher Akt expression as compared to tumors with negative HER2 (P 〈 0. 01 ). Levels of Akt were correlated with the downstream molecules 4EBP1 ( P 〈 0. 01 ) and pTOS6K ( P 〈 0. 05). 4EBP1 was mainly expressed in poorly differentiated tumors (P 〈0. 01 ) and correlated with tumor size (P 〈 0. 05), lymph node metastasis ( P 〈 0. 01 ) and locoregional recurrences ( P 〈 0. 01 ). Results suggest that 4EBP1 may be the main factor in PI-phosphoinositide-3-kinase (PI3K)-Akt-marmnalian targot of rapanycin signal transduetion pathways, which is associated with grade of malignancy and prognosis of breast cancer.
出处 《中华全科医师杂志》 2011年第5期356-358,共3页 Chinese Journal of General Practitioners
关键词 乳腺肿瘤 信号传导 Breast neoplasms Signal transduction
  • 相关文献

参考文献7

  • 1席广民,牛瑞芳.PI3K-Akt信号通路阻断在乳腺癌治疗中的作用[J].中华肿瘤防治杂志,2007,14(3):230-233. 被引量:12
  • 2Avdulov S,Li S,Michalek V,et al.Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells.Cancer Cell,2004,5:553-563. 被引量:1
  • 3Panigrahi AR,Pinder SE,Chan SY,et al.The role of PTEN and its signalling pathways,including AKT,in breast cancer:an assessment of relationships with other prognostic factors and with outcome.J Pathol,2004,204:93-100. 被引量:1
  • 4Nagata Y,Lan KH,Zhou X,et aL PTEN activation contributes to tumor inhibition by trastuzumab,and loss of PTEN predicts trastuzumab resistance in patients.Cancer Cell,2004,6:117-127. 被引量:1
  • 5Sarbassov DD,Guertin DA,Ali SM,et al.Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.Science,2005,307:1098-1101. 被引量:1
  • 6Castellvi J,Garcia A,Rojo F,et al.Phosphorylated 4E binding protein 1:a hallmark of cell signaling that correlates with survival in ovarian cancer.Cancer,2006,107:1801-1811. 被引量:1
  • 7Sarbassov DD,Ali SM,Sabatini DM.Growing roles for the mTOR pathway.Curr Opin Cell Biol,2005,17:596-603. 被引量:1

二级参考文献32

共引文献11

同被引文献11

  • 1Chen Y, Scully M, Petralia G, et al. Binding and inhibition of drug transport proteins by hepafin: a potential drug transporter modulator capable of reducing multidrug resistance in human cancer cells [ J ]. Cancer Biol Ther,2014;15(1) :135 - 145. 被引量:1
  • 2Norrby K. Low-molecular-weight heparins and angiogenesis [ J ]. AP- MIS,2006,114(2) :79 - 102. 被引量:1
  • 3Atkins M, Jones CA, Kirkpatrick P. Sunifinib maleate [ J ]. Nat Rev Drug Discov ,2006 ,5 (4) :279 - 280. 被引量:1
  • 4Jane EP, Premkumar DR, Pollack IF. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in hu- man malignant glioma cells [ J ]. J Pharmacol Exp Ther , 2006,319 (3) :1070 - 1080. 被引量:1
  • 5Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 [ J ]. Cancer Res, 2006,66(24) :11851 - 11858. 被引量:1
  • 6Moreno-Aspitia AL, Morton RF, Hillman DW, et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes:North Central Cancer Treatment Group and Mayo Clinic Trial N0336[ J]. J Clin 0ncol,2009,27( 1 ) : 11 - 15. 被引量:1
  • 7Huether A, Hopfner M, Baradari V, et al. Sorafenib alone or as combi- nation therapy for growth control of cholangioearcinoma [ J ]. Biochem Pharmacol,2007,73(9) :1308 - 13017. 被引量:1
  • 8Kakkar AKL, Levine MN, Kadziola Z, et al. Low molecular weight hep- arin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS) [ J ]. J Clin Oncol,2004,22(10) :1944 - 1948. 被引量:1
  • 9yon Tempelhoff GF, Harenberg J, Niemann F, et al. Effect of low mo- lecular weight heparin(Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery : A prospec- tive randomized double-blind trial [ J 1. lnt J Oncol, 2000,16 ( 4 ) : 815 - 824. 被引量:1
  • 10Chen YL, Seully M, Dawson G, et al. Perturbation of the heparin/ heparin-sulfate interactome of human breast cancer cells modulates pro-tumourigenlc effects associated with PI3K/Akt and MAPK/ERK signalling [ J ]. Thromb Haemost,2013,109 (6) : 1148 - 1157. 被引量:1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部